

SUPPLEMENTARY MATERIALS

PaCE CKD: A multinational survey of financial burden and work productivity in patients with chronic kidney disease and caregivers

Authors: *Steven Chadban,¹ Ciro Esposito,^{2,3} Ricardo Correa-Rotter,⁴ Mai-Szu Wu,⁵ Helmut Reichel,⁶ Hesham M. Elsayed,⁷ Juan Jose Garcia Sanchez,⁸ Surendra Pentakota,⁹ Thames Kularatne,¹⁰ Simon Fifer,¹⁰ Richard Hull¹¹*

(1) Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; (2) Nephrology, ICS Maugeri, Pavia, Italy; (3) Department of Internal Medicine and Therapy, University of Pavia, Italy (4) Department of Nephrology and Mineral Metabolism, National Medical Science and Nutrition Institute Salvador Zubirán, Mexico City, Mexico; (5) College of Medicine, Taipei Medical University, Taipei, Taiwan; (6) Nephrological Center, Villingen-Schwenningen, Germany; (7) Department of Internal Medicine and Nephrology, Faculty of Ain Shams University, Cairo, Egypt; (8) Global Market Access & Pricing, AstraZeneca, Barcelona, Spain; (9) Global Medical Affairs, Biopharmaceutical Medical, AstraZeneca, Cambridge, United Kingdom; (10) CaPPRe: Community and Patient Preference Research, Sydney, New South Wales, Australia; (11) Renal and Transplantation Unit, St George's University Hospital NHS Foundation Trust, London, United Kingdom

Corresponding author: Juan Jose Garcia Sanchez

Email: juanjose.garciasanchez@astrazeneca.com

List of figures

Figure S1. Self-reported disease severity distributions in patient (top) and caregiver (bottom) cohorts 3

List of tables

Table S1. Demographic characteristics, patient and general population cohorts.....	4
Table S2. Demographic characteristics, caregiver and general population cohorts.....	6
Table S3. Demographic characteristics, dialysis dependent and non-dialysis dependent patient subgroups	8
Table S4. Demographic characteristics, dialysis dependent and non-dialysis dependent caregiver subgroups	10
Table S5. STROBE statement – checklist of items that should be included in reports of observational studies	12
Table S6. Characterisation of caregiver support	14
Table S7. WPAI, patients (stratified by dialysis status) vs general population cohorts	15
Table S8. CFPB Financial Well-Being Scale, linear regression analysis for patients vs general population cohorts.....	16
Table S9. FACIT-COST, linear regression analysis for dialysis dependent patient subgroups	17
Table S10. WPAI, caregivers (stratified by dialysis status) vs general population cohorts.....	18
Table S11. CFPB Financial Well-Being Scale, linear regression analysis for caregivers vs general population cohorts.....	19



Figure S1. Self-reported disease severity distributions in patient (top) and caregiver (bottom) cohorts

Abbreviations: AUS, Australia; CKD, chronic kidney disease; DEU, Germany; EGY, Egypt; GBR, United Kingdom; ITA, Italy; TWN, Taiwan; USA, United States of America

Table S1. Demographic characteristics, patient and general population cohorts

Characteristic	AUS		DEU		EGY		GBR		ITA		TWN		USA	
	GP	Patients	GP	Patients	GP	Patients	GP	Patients	GP	Patients	GP	Patients	GP	Patients
Pop. size, n	150	150	201	201	221	222	212	212	129	129	190	190	199	199
Age group, n (%)														
< 20 yrs	4 (2.7)	1 (0.7)	1 (0.5)	0 (0.0)	7 (3.2)	0 (0.0)	4 (1.9)	2 (0.9)	1 (0.8)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.5)	0 (0.0)
20-29 yrs	22 (14.7)	26 (17.3)	11 (5.5)	13 (6.5)	45 (20.4)	33 (14.9)	17 (8.0)	15 (7.1)	2 (1.6)	7 (5.4)	4 (2.1)	3 (1.6)	7 (3.5)	4 (2.0)
30-39 yrs	32 (21.3)	31 (20.7)	35 (17.4)	34 (16.9)	68 (30.8)	87 (39.2)	64 (30.2)	68 (32.1)	14 (10.9)	10 (7.8)	6 (3.2)	7 (3.7)	30 (15.1)	34 (17.1)
40-49 yrs	14 (9.3)	33 (22.0)	38 (18.9)	46 (22.9)	87 (39.4)	60 (27.0)	21 (9.9)	70 (33.0)	34 (26.4)	19 (14.7)	102 (53.7)	37 (19.5)	21 (10.6)	31 (15.6)
50-59 yrs	28 (18.7)	21 (14.0)	57 (28.4)	63 (31.3)	12 (5.4)	30 (13.5)	38 (17.9)	20 (9.4)	31 (24.0)	39 (30.2)	45 (23.7)	88 (46.3)	30 (15.1)	39 (19.6)
60-69 yrs	37 (24.7)	25 (16.7)	51 (25.4)	37 (18.4)	2 (0.9)	11 (5.0)	56 (26.4)	25 (11.8)	22 (17.1)	29 (22.5)	14 (7.4)	36 (18.9)	70 (35.2)	51 (25.6)
70-79 yrs	11 (7.3)	13 (8.7)	8 (4.0)	7 (3.5)	0 (0.0)	1 (0.5)	12 (5.7)	10 (4.7)	23 (17.8)	17 (13.2)	19 (10.0)	19 (10.0)	33 (16.6)	39 (19.6)
≥ 80 yrs old	2 (1.3)	0 (0.0)	0 (0.0)	1 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.9)	2 (1.6)	8 (6.2)	0 (0.0)	0 (0.0)	7 (3.5)	1 (0.5)
Gender, n (%)														
Male	70 (46.7)	70 (46.7)	139 (69.2)	139 (69.2)	130 (58.8)	130 (58.6)	150 (70.8)	150 (70.8)	62 (48.1)	62 (48.1)	147 (77.4)	147 (77.4)	108 (54.3)	108 (54.3)
Female	80 (53.3)	80 (53.3)	62 (30.8)	62 (30.8)	91 (41.2)	92 (41.4)	62 (29.2)	62 (29.2)	67 (51.9)	67 (51.9)	43 (22.6)	43 (22.6)	90 (45.2)	91 (45.7)
Prefer not to answer	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.5)	0 (0.0)
Area of residence, n (%)														
Metro/city	107 (71.3)	107 (71.3)	120 (59.7)	120 (59.7)	219 (99.1)	220 (99.1)	123 (58.0)	123 (58.0)	91 (70.5)	91 (70.5)	156 (82.1)	156 (82.1)	77 (38.7)	77 (38.7)
Regional	26 (17.3)	32 (21.3)	46 (22.9)	43 (21.4)	2 (0.9)	0 (0.0)	50 (23.6)	63 (29.7)	26 (20.2)	33 (25.6)	26 (13.7)	34 (17.9)	76 (38.2)	73 (36.7)
Rural	17 (11.3)	11 (7.3)	35 (17.4)	38 (18.9)	0 (0.0)	2 (0.9)	39 (18.4)	26 (12.3)	12 (9.3)	5 (3.9)	8 (4.2)	0 (0.0)	46 (23.1)	49 (24.6)
Employment status, n (%)														
Employed	100 (66.7)	94 (62.7)	154 (76.6)	107 (53.2)	185 (83.7)	117 (52.7)	139 (65.6)	148 (69.8)	73 (56.6)	56 (43.4)	161 (84.7)	125 (65.8)	97 (48.7)	77 (38.7)

Characteristic	AUS		DEU		EGY		GBR		ITA		TWN		USA	
	GP	Patients	GP	Patients	GP	Patients	GP	Patients	GP	Patients	GP	Patients	GP	Patients
Retired	27 (18.0)	24 (16.0)	29 (14.4)	39 (19.4)	3 (1.4)	10 (4.5)	49 (23.1)	23 (10.8)	31 (24.0)	32 (24.8)	18 (9.5)	55 (28.9)	79 (39.7)	70 (35.2)
Not working, due to medical reasons	0 (0.0)	24 (16.0)	0 (0.0)	25 (12.4)	0 (0.0)	11 (5.0)	0 (0.0)	29 (13.7)	0 (0.0)	30 (23.3)	0 (0.0)	4 (2.1)	1 (0.5)	35 (17.6)
Not working	6 (4.0)	2 (1.3)	8 (4.0)	15 (7.5)	10 (4.5)	56 (25.2)	9 (4.2)	8 (3.8)	8 (6.2)	4 (3.1)	5 (2.6)	0 (0.0)	10 (5.0)	8 (4.0)
Student	4 (2.7)	1 (0.7)	3 (1.5)	3 (1.5)	17 (7.7)	13 (5.9)	5 (2.4)	1 (0.5)	1 (0.8)	0 (0.0)	0 (0.0)	1 (0.5)	1 (0.5)	3 (1.5)
Home duties and/or caring responsibilities	9 (6.0)	3 (2.0)	4 (2.0)	5 (2.5)	4 (1.8)	13 (5.9)	10 (4.7)	2 (0.9)	15 (11.6)	2 (1.6)	2 (1.1)	0 (0.0)	7 (3.5)	1 (0.5)
Other	4 (2.7)	2 (1.3)	3 (1.5)	7 (3.5)	2 (0.9)	2 (0.9)	0 (0.0)	1 (0.5)	1 (0.8)	5 (3.9)	4 (2.1)	5 (2.6)	4 (2.0)	5 (2.5)
Income, n (%)														
Nil income	3 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.5)	0 (0.0)	0 (0.0)	3 (1.4)	1 (0.8)	22 (17.1)	5 (2.6)	1 (0.5)	0 (0.0)	2 (1.0)
Below threshold†	57 (38.0)	61 (40.7)	82 (40.8)	80 (39.8)	44 (19.9)	128 (57.7)	98 (46.2)	63 (29.7)	52 (40.3)	42 (32.6)	42 (22.1)	41 (21.6)	94 (47.2)	124 (62.3)
Threshold† and above	78 (52.0)	85 (56.7)	105 (52.2)	108 (53.7)	94 (42.5)	20 (9.0)	105 (49.5)	143 (67.5)	66 (51.2)	35 (27.1)	141 (74.2)	46 (24.2)	88 (44.2)	71 (35.7)
Prefer not to answer	12 (8.0)	4 (2.7)	14 (7.0)	13 (6.5)	82 (37.1)	74 (33.3)	9 (4.2)	3 (1.4)	10 (7.8)	30 (23.3)	2 (1.1)	102 (53.7)	17 (8.5)	2 (1.0)

Abbreviations: AUS, Australia; DEU, Germany; EGY, Egypt; GBR, United Kingdom; GP, general population; ITA, Italy; TWN, Taiwan; USA, United States of America

† Income above and below for each country: AUS, \$72,800; DEU, €40,000; EGY, E£800,000; GBR, £40,000; ITA, €32,000; TWN, NT\$800,000; USA, \$75,000

Table S2. Demographic characteristics, caregiver and general population cohorts

Characteristic	AUS		DEU		EGY		GBR		ITA		TWN		USA	
	GP	Carers	GP	Carers	GP	Carers	GP	Carers	GP	Carers	GP	Carers	GP	Carers
Pop. size, n	53	53	99	99	97	97	116	116	101	102	94	94	113	113
Age group, n (%)														
< 20 yrs	1 (1.9)	1 (1.9)	0 (0.0)	0 (0.0)	2 (2.1)	2 (2.1)	0 (0.0)	1 (0.9)	0 (0.0)	2 (2.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.9)
20-29 yrs	9 (17.0)	7 (13.2)	10 (10.1)	6 (6.1)	15 (15.5)	24 (24.7)	19 (16.4)	25 (21.6)	8 (7.9)	11 (10.8)	7 (7.4)	6 (6.4)	8 (7.1)	11 (9.7)
30-39 yrs	15 (28.3)	17 (32.1)	23 (23.2)	27 (27.3)	45 (46.4)	36 (37.1)	47 (40.5)	40 (34.5)	16 (15.8)	11 (10.8)	19 (20.2)	20 (21.3)	52 (46.0)	48 (42.5)
40-49 yrs	8 (15.1)	10 (18.9)	13 (13.1)	24 (24.2)	30 (30.9)	18 (18.6)	5 (4.3)	33 (28.4)	28 (27.7)	23 (22.5)	32 (34.0)	30 (31.9)	5 (4.4)	22 (19.5)
50-59 yrs	3 (5.7)	9 (17.0)	27 (27.3)	27 (27.3)	5 (5.2)	14 (14.4)	16 (13.8)	11 (9.5)	32 (31.7)	34 (33.3)	26 (27.7)	17 (18.1)	15 (13.3)	14 (12.4)
60-69 yrs	14 (26.4)	6 (11.3)	25 (25.3)	14 (14.1)	0 (0.0)	3 (3.1)	27 (23.3)	4 (3.4)	15 (14.9)	18 (17.6)	7 (7.4)	18 (19.1)	28 (24.8)	12 (10.6)
70-79 yrs	2 (3.8)	3 (5.7)	1 (1.0)	1 (1.0)	0 (0.0)	0 (0.0)	2 (1.7)	2 (1.7)	2 (2.0)	2 (2.0)	3 (3.2)	3 (3.2)	3 (2.7)	4 (3.5)
≥ 80 yrs old	1 (1.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.0)	0 (0.0)	0 (0.0)	2 (1.8)	1 (0.9)
Gender, n (%)														
Male	27 (50.9)	27 (50.9)	55 (55.6)	55 (55.6)	31 (32.0)	31 (32.0)	57 (49.1)	57 (49.1)	20 (19.8)	21 (20.6)	33 (35.1)	33 (35.1)	53 (46.9)	53 (46.9)
Female	26 (49.1)	26 (49.1)	44 (44.4)	44 (44.4)	66 (68.0)	66 (68.0)	59 (50.9)	59 (50.9)	81 (80.2)	81 (79.4)	61 (64.9)	61 (64.9)	60 (53.1)	60 (53.1)
Prefer not to answer	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Area of residence, n (%)														
Metro/city	36 (67.9)	36 (67.9)	58 (58.6)	58 (58.6)	92 (94.8)	92 (94.8)	48 (41.4)	48 (41.4)	53 (52.5)	53 (52.0)	68 (72.3)	68 (72.3)	59 (52.2)	59 (52.2)
Regional	12 (22.6)	15 (28.3)	24 (24.2)	35 (35.4)	2 (2.1)	3 (3.1)	47 (40.5)	56 (48.3)	26 (25.7)	42 (41.2)	17 (18.1)	26 (27.7)	29 (25.7)	41 (36.3)
Rural	5 (9.4)	2 (3.8)	17 (17.2)	6 (6.1)	3 (3.1)	2 (2.1)	21 (18.1)	12 (10.3)	22 (21.8)	7 (6.9)	9 (9.6)	0 (0.0)	25 (22.1)	13 (11.5)
Employment status, n (%)														
Employed	38 (71.7)	40 (75.5)	69 (69.7)	71 (71.7)	86 (88.7)	45 (46.4)	84 (72.4)	92 (79.3)	64 (63.4)	72 (70.6)	87 (92.6)	67 (71.3)	66 (58.4)	96 (85.0)

Characteristic	AUS		DEU		EGY		GBR		ITA		TWN		USA	
	GP	Carers	GP	Carers	GP	Carers	GP	Carers	GP	Carers	GP	Carers	GP	Carers
Retired	13 (24.5)	5 (9.4)	16 (16.2)	15 (15.2)	0 (0.0)	0 (0.0)	19 (16.4)	4 (3.4)	7 (6.9)	11 (10.8)	4 (4.3)	23 (24.5)	25 (22.1)	9 (8.0)
Not working, due to medical reasons	0 (0.0)	2 (3.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (3.4)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)	2 (1.8)
Not working	0 (0.0)	1 (1.9)	8 (8.1)	6 (6.1)	3 (3.1)	37 (38.1)	8 (6.9)	4 (3.4)	12 (11.9)	7 (6.9)	0 (0.0)	0 (0.0)	10 (8.8)	2 (1.8)
Student	1 (1.9)	0 (0.0)	4 (4.0)	0 (0.0)	5 (5.2)	7 (7.2)	1 (0.9)	1 (0.9)	2 (2.0)	5 (4.9)	1 (1.1)	1 (1.1)	3 (2.7)	0 (0.0)
Home duties and/or caring responsibilities	1 (1.9)	5 (9.4)	2 (2.0)	3 (3.0)	3 (3.1)	8 (8.2)	4 (3.4)	10 (8.6)	14 (13.9)	5 (4.9)	1 (1.1)	1 (1.1)	6 (5.3)	3 (2.7)
Other	0 (0.0)	0 (0.0)	0 (0.0)	4 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.9)	2 (2.0)	2 (2.0)	1 (1.1)	1 (1.1)	3 (2.7)	1 (0.9)
Income, n (%)														
Nil income	17 (32.1)	17 (32.1)	1 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.9)	0 (0.0)	1 (1.0)	2 (2.0)	0 (0.0)	0 (0.0)	4 (3.5)	0 (0.0)
Below threshold†	28 (52.8)	33 (62.3)	54 (54.5)	25 (25.3)	22 (22.7)	69 (71.1)	47 (40.5)	52 (44.8)	63 (62.4)	30 (29.4)	30 (31.9)	24 (25.5)	46 (40.7)	43 (38.1)
Threshold† and above	8 (15.1)	3 (5.7)	38 (38.4)	60 (60.6)	59 (60.8)	15 (15.5)	60 (51.7)	64 (55.2)	22 (21.8)	47 (46.1)	63 (67.0)	58 (61.7)	52 (46.0)	68 (60.2)
Prefer not to answer	0 (0.0)	0 (0.0)	6 (6.1)	14 (14.1)	16 (16.5)	13 (13.4)	8 (6.9)	0 (0.0)	15 (14.9)	23 (22.5)	1 (1.1)	12 (12.8)	11 (9.7)	2 (1.8)

Abbreviations: AUS, Australia; DEU, Germany; EGY, Egypt; GBR, United Kingdom; GP, general population; ITA, Italy; TWN, Taiwan; GBR, United Kingdom; USA, United States of America

† Income above and below for each country: AUS, \$72,800; DEU, €40,000; EGY, E£800,000; GBR, £40,000; ITA, €32,000; TWN, NT\$800,000; USA, \$75,000

Table S3. Demographic characteristics, dialysis dependent and non-dialysis dependent patient subgroups

Characteristic	AUS		DEU		EGY		GBR		ITA		TWN		USA	
	DD	NDD	DD	NDD	DD	NDD	DD	NDD	DD	NDD	DD	NDD	DD	NDD
Pop. size, n	45	105	85	116	124	98	114	98	41	88	29	161	64	135
Age group, n (%)														
< 20 yrs	0 (0.0)	1 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.9)	1 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
20-29 yrs	13 (28.9)	13 (12.4)	7 (8.2)	6 (5.2)	15 (12.1)	18 (18.4)	8 (7.0)	7 (7.1)	1 (2.4)	6 (6.8)	2 (6.9)	1 (0.6)	3 (4.7)	1 (0.7)
30-39 yrs	12 (26.7)	19 (18.1)	14 (16.5)	20 (17.2)	43 (34.7)	44 (44.9)	45 (39.5)	23 (23.5)	2 (4.9)	8 (9.1)	3 (10.3)	4 (2.5)	22 (34.4)	12 (8.9)
40-49 yrs	16 (35.6)	17 (16.2)	16 (18.8)	30 (25.9)	38 (30.6)	22 (22.4)	53 (46.5)	17 (17.3)	9 (22.0)	10 (11.4)	1 (3.4)	36 (22.4)	17 (26.6)	14 (10.4)
50-59 yrs	3 (6.7)	18 (17.1)	28 (32.9)	35 (30.2)	20 (16.1)	10 (10.2)	5 (4.4)	15 (15.3)	8 (19.5)	31 (35.2)	2 (6.9)	86 (53.4)	10 (15.6)	29 (21.5)
60-69 yrs	1 (2.2)	24 (22.9)	18 (21.2)	19 (16.4)	7 (5.6)	4 (4.1)	1 (0.9)	24 (24.5)	11 (26.8)	18 (20.5)	11 (37.9)	25 (15.5)	10 (15.6)	41 (30.4)
70-79 yrs	0 (0.0)	13 (12.4)	2 (2.4)	5 (4.3)	1 (0.8)	0 (0.0)	1 (0.9)	9 (9.2)	7 (17.1)	10 (11.4)	10 (34.5)	9 (5.6)	2 (3.1)	37 (27.4)
≥ 80 yrs old	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.9)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.0)	3 (7.3)	5 (5.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.7)
Gender, n (%)														
Male	31 (68.9)	39 (37.1)	77 (90.6)	62 (53.4)	71 (57.3)	59 (60.2)	95 (83.3)	55 (56.1)	19 (46.3)	43 (48.9)	15 (51.7)	132 (82.0)	48 (75.0)	60 (44.4)
Female	14 (31.1)	66 (62.9)	8 (9.4)	54 (46.6)	53 (42.7)	39 (39.8)	19 (16.7)	43 (43.9)	22 (53.7)	45 (51.1)	14 (48.3)	29 (18.0)	16 (25.0)	75 (55.6)
Area of residence, n (%)														
Metro/city	36 (80.0)	71 (67.6)	53 (62.4)	67 (57.8)	124 (100.0)	96 (98.0)	90 (78.9)	33 (33.7)	22 (53.7)	69 (78.4)	23 (79.3)	133 (82.6)	29 (45.3)	48 (35.6)
Regional	7 (15.6)	25 (23.8)	15 (17.6)	28 (24.1)	0 (0.0)	0 (0.0)	20 (17.5)	43 (43.9)	17 (41.5)	16 (18.2)	6 (20.7)	28 (17.4)	30 (46.9)	43 (31.9)
Rural	2 (4.4)	9 (8.6)	17 (20.0)	21 (18.1)	0 (0.0)	2 (2.0)	4 (3.5)	22 (22.4)	2 (4.9)	3 (3.4)	0 (0.0)	0 (0.0)	5 (7.8)	44 (32.6)
Employment status, n (%)														
Employed	36 (80.0)	58 (55.2)	47 (55.3)	60 (51.7)	56 (45.2)	61 (62.2)	98 (86.0)	50 (51.0)	13 (31.7)	43 (48.9)	5 (17.2)	120 (74.5)	39 (60.9)	38 (28.1)
Retired	2 (4.4)	22 (21.0)	24 (28.2)	15 (12.9)	9 (7.3)	1 (1.0)	1 (0.9)	22 (22.4)	13 (31.7)	19 (21.6)	20 (69.0)	35 (21.7)	9 (14.1)	61 (45.2)

Characteristic	AUS		DEU		EGY		GBR		ITA		TWN		USA	
	DD	NDD	DD	NDD	DD	NDD	DD	NDD	DD	NDD	DD	NDD	DD	NDD
Not working, due to medical reasons	5 (11.1)	19 (18.1)	11 (12.9)	14 (12.1)	8 (6.5)	3 (3.1)	10 (8.8)	19 (19.4)	9 (22.0)	21 (23.9)	3 (10.3)	1 (0.6)	9 (14.1)	26 (19.3)
Not working	2 (4.4)	0 (0.0)	2 (2.4)	13 (11.2)	35 (28.2)	21 (21.4)	5 (4.4)	3 (3.1)	3 (7.3)	1 (1.1)	0 (0.0)	0 (0.0)	2 (3.1)	6 (4.4)
Student	0 (0.0)	1 (1.0)	0 (0.0)	3 (2.6)	10 (8.1)	3 (3.1)	0 (0.0)	1 (1.0)	0 (0.0)	0 (0.0)	1 (3.4)	0 (0.0)	1 (1.6)	2 (1.5)
Home duties and/or caring responsibilities	0 (0.0)	3 (2.9)	0 (0.0)	5 (4.3)	4 (3.2)	9 (9.2)	0 (0.0)	2 (2.0)	1 (2.4)	1 (1.1)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.7)
Other	0 (0.0)	2 (1.9)	1 (1.2)	6 (5.2)	2 (1.6)	0 (0.0)	0 (0.0)	1 (1.0)	2 (4.9)	3 (3.4)	0 (0.0)	5 (3.1)	4 (6.3)	1 (0.7)
Income, n (%)														
Nil income	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (3.1)	1 (2.4)	21 (23.9)	1 (3.4)	0 (0.0)	0 (0.0)	2 (1.5)
Below threshold†	10 (22.2)	51 (48.6)	34 (40.0)	46 (39.7)	65 (52.4)	63 (64.3)	16 (14.0)	47 (48.0)	15 (36.6)	27 (30.7)	10 (34.5)	31 (19.3)	21 (32.8)	103 (76.3)
Threshold† and above	33 (73.3)	52 (49.5)	46 (54.1)	62 (53.4)	12 (9.7)	8 (8.2)	96 (84.2)	47 (48.0)	14 (34.1)	21 (23.9)	15 (51.7)	31 (19.3)	43 (67.2)	28 (20.7)
Prefer not to answer	2 (4.4)	2 (1.9)	5 (5.9)	8 (6.9)	47 (37.9)	27 (27.6)	2 (1.8)	1 (1.0)	11 (26.8)	19 (21.6)	3 (10.3)	99 (61.5)	0 (0.0)	2 (1.5)

Abbreviations: AUS, Australia; DD, dialysis dependent; DEU, Germany; EGY, Egypt; GBR, United Kingdom; ITA, Italy; NDD, non-dialysis dependent; TWN, Taiwan; USA, United States of America

† Income above and below for each country: AUS, \$72,800; DEU, €40,000; EGY, E£800,000; GBR, £40,000; ITA, €32,000; TWN, NT\$800,000; USA, \$75,000

Table S4. Demographic characteristics, dialysis dependent and non-dialysis dependent caregiver subgroups

Characteristic	AUS		DEU		EGY		GBR		ITA		TWN		USA	
	DD	NDD	DD	NDD	DD	NDD	DD	NDD	DD	NDD	DD	NDD	DD	NDD
Pop. size, n	34	19	64	35	52	45	78	38	25	77	45	49	92	21
Age group, n (%)														
< 20 yrs	1 (2.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (4.4)	1 (1.3)	0 (0.0)	0 (0.0)	2 (2.6)	0 (0.0)	0 (0.0)	1 (1.1)	0 (0.0)
20-29 yrs	6 (17.6)	1 (5.3)	4 (6.3)	2 (5.7)	10 (19.2)	14 (31.1)	17 (21.8)	8 (21.1)	6 (24.0)	5 (6.5)	3 (6.7)	3 (6.1)	11 (12.0)	0 (0.0)
30-39 yrs	15 (44.1)	2 (10.5)	24 (37.5)	3 (8.6)	22 (42.3)	14 (31.1)	34 (43.6)	6 (15.8)	4 (16.0)	7 (9.1)	11 (24.4)	9 (18.4)	46 (50.0)	2 (9.5)
40-49 yrs	7 (20.6)	3 (15.8)	11 (17.2)	13 (37.1)	10 (19.2)	8 (17.8)	20 (25.6)	13 (34.2)	6 (24.0)	17 (22.1)	16 (35.6)	14 (28.6)	20 (21.7)	2 (9.5)
50-59 yrs	3 (8.8)	6 (31.6)	14 (21.9)	13 (37.1)	10 (19.2)	4 (8.9)	4 (5.1)	7 (18.4)	6 (24.0)	28 (36.4)	7 (15.6)	10 (20.4)	8 (8.7)	6 (28.6)
60-69 yrs	0 (0.0)	6 (31.6)	10 (15.6)	4 (11.4)	0 (0.0)	3 (6.7)	1 (1.3)	3 (7.9)	1 (4.0)	17 (22.1)	7 (15.6)	11 (22.4)	5 (5.4)	7 (33.3)
70-79 yrs	2 (5.9)	1 (5.3)	1 (1.6)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.3)	1 (2.6)	1 (4.0)	1 (1.3)	1 (2.2)	2 (4.1)	1 (1.1)	3 (14.3)
≥ 80 yrs old	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (4.8)
Gender, n (%)														
Male	20 (58.8)	7 (36.8)	39 (60.9)	16 (45.7)	21 (40.4)	10 (22.2)	47 (60.3)	10 (26.3)	6 (24.0)	15 (19.5)	17 (37.8)	16 (32.7)	49 (53.3)	4 (19.0)
Female	14 (41.2)	12 (63.2)	25 (39.1)	19 (54.3)	31 (59.6)	35 (77.8)	31 (39.7)	28 (73.7)	19 (76.0)	62 (80.5)	28 (62.2)	33 (67.3)	43 (46.7)	17 (81.0)
Area of residence, n (%)														
Metro/city	23 (67.6)	13 (68.4)	38 (59.4)	20 (57.1)	50 (96.2)	42 (93.3)	37 (47.4)	11 (28.9)	12 (48.0)	41 (53.2)	30 (66.7)	38 (77.6)	54 (58.7)	5 (23.8)
Regional	11 (32.4)	4 (21.1)	24 (37.5)	11 (31.4)	1 (1.9)	2 (4.4)	36 (46.2)	20 (52.6)	11 (44.0)	31 (40.3)	15 (33.3)	11 (22.4)	31 (33.7)	10 (47.6)
Rural	0 (0.0)	2 (10.5)	2 (3.1)	4 (11.4)	1 (1.9)	1 (2.2)	5 (6.4)	7 (18.4)	2 (8.0)	5 (6.5)	0 (0.0)	0 (0.0)	7 (7.6)	6 (28.6)
Employment status, n (%)														
Employed	31 (91.2)	9 (47.4)	42 (65.6)	29 (82.9)	32 (61.5)	13 (28.9)	68 (87.2)	24 (63.2)	17 (68.0)	55 (71.4)	35 (77.8)	32 (65.3)	85 (92.4)	11 (52.4)
Retired	2 (5.9)	3 (15.8)	11 (17.2)	4 (11.4)	0 (0.0)	0 (0.0)	0 (0.0)	4 (10.5)	3 (12.0)	8 (10.4)	9 (20.0)	14 (28.6)	1 (1.1)	8 (38.1)

Characteristic	AUS		DEU		EGY		GBR		ITA		TWN		USA	
	DD	NDD	DD	NDD	DD	NDD	DD	NDD	DD	NDD	DD	NDD	DD	NDD
Not working, due to medical reasons	0 (0.0)	2 (10.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.6)	2 (5.3)	0 (0.0)	0 (0.0)	1 (2.2)	0 (0.0)	1 (1.1)	1 (4.8)
Not working	0 (0.0)	1 (5.3)	6 (9.4)	0 (0.0)	14 (26.9)	23 (51.1)	3 (3.8)	1 (2.6)	3 (12.0)	4 (5.2)	0 (0.0)	0 (0.0)	2 (2.2)	0 (0.0)
Student	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5 (9.6)	2 (4.4)	1 (1.3)	0 (0.0)	2 (8.0)	3 (3.9)	0 (0.0)	1 (2.0)	0 (0.0)	0 (0.0)
Home duties and/or caring responsibilities	1 (2.9)	4 (21.1)	2 (3.1)	1 (2.9)	1 (1.9)	7 (15.6)	3 (3.8)	7 (18.4)	0 (0.0)	5 (6.5)	0 (0.0)	1 (2.0)	2 (2.2)	1 (4.8)
Other	0 (0.0)	0 (0.0)	3 (4.7)	1 (2.9)	0 (0.0)	0 (0.0)	1 (1.3)	0 (0.0)	0 (0.0)	2 (2.6)	0 (0.0)	1 (2.0)	1 (1.1)	0 (0.0)
Income, n (%)														
Nil income	7 (20.6)	10 (52.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Below threshold†	24 (70.6)	9 (47.4)	17 (26.6)	8 (22.9)	27 (51.9)	42 (93.3)	29 (37.2)	23 (60.5)	6 (24.0)	24 (31.2)	12 (26.7)	12 (24.5)	30 (32.6)	13 (61.9)
Threshold† and above	3 (8.8)	0 (0.0)	34 (53.1)	26 (74.3)	14 (26.9)	1 (2.2)	49 (62.8)	15 (39.5)	10 (40.0)	37 (48.1)	29 (64.4)	29 (59.2)	60 (65.2)	8 (38.1)
Prefer not to answer	0 (0.0)	0 (0.0)	13 (20.3)	1 (2.9)	11 (21.2)	2 (4.4)	0 (0.0)	0 (0.0)	9 (36.0)	14 (18.2)	4 (8.9)	8 (16.3)	2 (2.2)	0 (0.0)

Abbreviations: AUS, Australia; DD, dialysis dependent; DEU, Germany; EGY, Egypt; GBR, United Kingdom; ITA, Italy; NDD, non-dialysis dependent; TWN, Taiwan; USA, United States of America

† Income above and below for each country: AUS, \$72,800; DEU, €40,000; EGY, E£800,000; GBR, £40,000; ITA, €32,000; TWN, NT\$800,000; USA, \$75,000

Table S5. STROBE statement – checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
		Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
		Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed	N/A
		Case-control study—For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8†	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	8
Study size	10	Explain how the study size was arrived at	8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	7
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed	8
		Case-control study—If applicable, explain how matching of cases and controls was addressed	
		Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	N/A
Results			
Participants	13†	(a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8-9
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14†	(a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders	10-11

	Item No	Recommendation	Page No
		(b) Indicate number of participants with missing data for each variable of interest	<i>N/A</i>
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	<i>N/A</i>
Outcome data	15 [†]	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	<i>N/A</i>
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	<i>N/A</i>
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	<i>11-14</i>
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included	<i>Tables, supplement</i>
		(b) Report category boundaries when continuous variables were categorized	<i>22-26</i>
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	<i>N/A</i>
Other analyses	17	Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses	<i>11-14</i>
Discussion			
Key results	18	Summarise key results with reference to study objectives	<i>15</i>
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	<i>17-18</i>
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	<i>15-17</i>
Generalisability	21	Discuss the generalisability (external validity) of the study results	<i>13-14</i>
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	<i>19</i>

[†] Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org

Table S6. Characterisation of caregiver support

What sort of care/support do you provide for the person you care for? n (%)	AUS	DEU	EGY	GBR	ITA	TWN	USA
Accompany or drive them to medical appointments	49 (92.5)	89 (89.9)	83 (85.6)	89 (76.7)	79 (77.5)	75 (79.8)	101 (89.4)
Advocacy (e.g. helping them dispute a treatment or a decision)	19 (35.8)	33 (33.3)	36 (37.1)	42 (36.2)	58 (56.9)	5 (5.3)	52 (46.0)
Behavioural support (e.g. dealing with behaviours such as aggression or social withdrawal)	19 (35.8)	22 (22.2)	23 (23.7)	32 (27.6)	17 (16.7)	1 (1.1)	45 (39.8)
Encourage them to seek help or talk about their feelings	26 (49.1)	46 (46.5)	26 (26.8)	70 (60.3)	34 (33.3)	14 (14.9)	58 (51.3)
Help them get to social gatherings	24 (45.3)	37 (37.4)	26 (26.8)	48 (41.4)	36 (35.3)	18 (19.1)	55 (48.7)
Help them get to work	4 (7.5)	12 (12.1)	10 (10.3)	15 (12.9)	2 (2.0)	0 (0.0)	20 (17.7)
Help with communication (e.g. reading, writing, helping them articulate themselves in conversations)	20 (37.7)	37 (37.4)	23 (23.7)	39 (33.6)	11 (10.8)	5 (5.3)	46 (40.7)
Help with dependants and childcare	11 (20.8)	26 (26.3)	30 (30.9)	34 (29.3)	15 (14.7)	9 (9.6)	35 (31.0)
Help with general household duties (e.g. cleaning, food preparation, running errands, shopping, laundry)	38 (71.7)	67 (67.7)	52 (53.6)	95 (81.9)	48 (47.1)	70 (74.5)	91 (80.5)
Help with medications (e.g. remind, organise or help them take medications)	37 (69.8)	87 (87.9)	84 (86.6)	102 (87.9)	57 (55.9)	52 (55.3)	100 (88.5)
Help with mobility (e.g. walking, getting out of bed)	25 (47.2)	40 (40.4)	45 (46.4)	61 (52.6)	20 (19.6)	5 (5.3)	59 (52.2)
Help with organising and handling finances (e.g. budgeting, assisting with online banking, making financial decisions for them, managing their accounts)	21 (39.6)	44 (44.4)	11 (11.3)	45 (38.8)	48 (47.1)	3 (3.2)	47 (41.6)
Help with personal care (e.g. eating, showering, dressing)	20 (37.7)	42 (42.4)	55 (56.7)	50 (43.1)	22 (21.6)	22 (23.4)	57 (50.4)
Help with property maintenance (e.g. as mowing lawns, cleaning gutters etc.)	23 (43.4)	31 (31.3)	27 (27.8)	71 (61.2)	19 (18.6)	3 (3.2)	58 (51.3)
Pay for medical bills (e.g., tests, doctor fees, hospital bills etc.)	22 (41.5)	47 (47.5)	29 (29.9)	27 (23.3)	4 (3.9)	74 (78.7)	43 (38.1)
Pay for medicines (e.g., prescription and over the counter medicine)	31 (58.5)	66 (66.7)	26 (26.8)	36 (31.0)	11 (10.8)	72 (76.6)	47 (41.6)
Pay for non-medical bills (e.g., electricity, water, insurance, phone, internet etc.)	25 (47.2)	38 (38.4)	21 (21.6)	33 (28.4)	6 (5.9)	52 (55.3)	37 (32.7)
Picking up medications	39 (73.6)	82 (82.8)	71 (73.2)	95 (81.9)	62 (60.8)	49 (52.1)	93 (82.3)
Provide administrative support (e.g. filling out forms, sending emails or making phone calls on their behalf)	28 (52.8)	59 (59.6)	34 (35.1)	66 (56.9)	63 (61.8)	19 (20.2)	64 (56.6)
Provide emotional support (e.g. listening and talking to them)	40 (75.5)	72 (72.7)	72 (74.2)	91 (78.4)	71 (69.6)	83 (88.3)	89 (78.8)
Provide other financial support	21 (39.6)	59 (59.6)	12 (12.4)	34 (29.3)	15 (14.7)	21 (22.3)	42 (37.2)
Schedule medical appointments	29 (54.7)	79 (79.8)	56 (57.7)	74 (63.8)	45 (44.1)	29 (30.9)	88 (77.9)
Take them to the hospital during emergencies	35 (66.0)	67 (67.7)	49 (50.5)	76 (65.5)	54 (52.9)	18 (19.1)	70 (61.9)
Talking to healthcare professionals	35 (66.0)	43 (43.4)	77 (79.4)	81 (69.8)	69 (67.6)	48 (51.1)	89 (78.8)
Other	1 (1.9)	1 (1.0)	0 (0.0)	1 (0.9)	3 (2.9)	0 (0.0)	0 (0.0)

Abbreviations: AUS, Australia; DEU, Germany; EGY, Egypt; GBR, United Kingdom; ITA, Italy; TWN, Taiwan; USA, United States of America

Table S7. WPAI, patients (stratified by dialysis status) vs general population cohorts

Country		Absenteeism			Presenteeism			Work activity impairment			Activity impairment		
		GP	DD	NDD	GP	DD	NDD	GP	DD	NDD	GP	DD	NDD
AUS	Mean (SD)	4.4 (15.8)	22.6 (13.8)	8.7 (17.4)	10.6 (19.4)	63.7 (22.4)	25.1 (24.1)	9.3 (15.8)	48.8 (18.3)	21.2 (20.8)	10.3 (17.4)	63.1 (21.8)	35.5 (29.0)
	Median (range)	0.0 (0.0, 100.0)	22.2 (0.0, 50.0)	0.0 (0.0, 81.5)	0.0 (0.0, 80.0)	60.0 (20.0, 90.0)	20.0 (0.0, 80.0)	0.0 (0.0, 80.0)	51.9 (16.8, 87.8)	115.5 (0.0, 61.9)	0.0 (0.0, 70.0)	70.0 (20.0, 100.0)	30.0 (0.0, 100.0)
DEU	Mean (SD)	6.3 (19.1)	17.8 (25.3)	15.6 (19.1)	80.0 (0.0)	38.8 (25.7)	42.2 (30.8)	7.6 (15.1)	31.2 (21.1)	33.6 (24.1)	11.0 (18.2)	51.3 (26.9)	48.6 (29.8)
	Median (range)	0.0 (0.0, 100.0)	8.2 (0.0, 100.0)	11.8 (0.0, 62.5)	7.6 (15.1, 0.0)	40.0 (0.0, 90.0)	40.0 (0.0, 90.0)	0.0 (0.0, 80.0)	30.0 (0.0, 75.5)	30.0 (0.0, 85.8)	0.0 (0.0, 80.0)	60.0 (0.0, 100.0)	50.0 (0.0, 100.0)
EGY	Mean (SD)	11.8 (17.8)	20.4 (18.4)	16.3 (17.0)	100.0 (0.0)	54.4 (25.1)	39.7 (25.2)	10.4 (15.1)	41.4 (17.9)	31.6 (20.1)	14.1 (20.2)	52.1 (26.1)	43.4 (26.5)
	Median (range)	2.3 (0.0, 66.7)	17.6 (0.0, 66.7)	15.5 (0.0, 70.6)	10.4 (15.1, 7.8)	60.0 (10.0, 100.0)	30.0 (0.0, 80.0)	7.8 (0.0, 100.0)	44.2 (7.3, 75.2)	25.7 (0.0, 76.6)	10.0 (0.0, 100.0)	55.0 (0.0, 100.0)	50.0 (0.0, 100.0)
GBR	Mean (SD)	3.2 (13.5)	24.5 (20.0)	17.0 (24.8)	80.0 (0.0)	55.0 (25.4)	42.6 (34.7)	7.0 (15.1)	40.2 (19.0)	31.4 (26.4)	6.9 (14.1)	58.6 (24.4)	47.1 (32.0)
	Median (range)	0.0 (0.0, 100.0)	16.7 (0.0, 100.0)	2.4 (0.0, 100.0)	7.0 (15.1, 0.0)	50.0 (10.0, 100.0)	50.0 (0.0, 100.0)	0.0 (0.0, 80.0)	37.7 (7.6, 88.0)	30.2 (0.0, 100.0)	0.0 (0.0, 80.0)	60.0 (0.0, 100.0)	50.0 (0.0, 100.0)
ITA	Mean (SD)	4.0 (13.0)	24.7 (22.5)	5.6 (9.8)	100.0 (0.0)	47.3 (16.8)	27.8 (27.8)	14.8 (21.2)	33.6 (11.0)	25.7 (25.7)	14.4 (19.3)	57.3 (22.3)	49.0 (33.6)
	Median (range)	0.0 (0.0, 55.6)	22.2 (0.0, 60.0)	0.0 (0.0, 34.5)	14.8 (21.2, 9.9)	50.0 (20.0, 70.0)	20.0 (0.0, 100.0)	9.9 (0.0, 100.0)	30.5 (19.1, 57.4)	20.0 (0.0, 80.2)	10.0 (0.0, 90.0)	60.0 (10.0, 100.0)	50.0 (0.0, 100.0)
TWN	Mean (SD)	0.8 (3.3)	22.6 (8.4)	2.0 (11.1)	100.0 (0.0)	65.0 (7.1)	21.3 (22.0)	14.5 (19.2)	50.2 (0.1)	20.7 (21.0)	13.5 (17.9)	68.3 (7.1)	34.2 (19.7)
	Median (range)	0.0 (0.0, 22.2)	22.6 (16.7, 28.6)	0.0 (0.0, 100.0)	14.5 (19.2, 10.0)	65.0 (60.0, 70.0)	10.0 (0.0, 80.0)	10.0 (0.0, 100.0)	50.2 (50.2, 50.3)	10.0 (0.0, 70.0)	10.0 (0.0, 100.0)	70.0 (50.0, 80.0)	30.0 (10.0, 80.0)
USA	Mean (SD)	3.6 (14.0)	21.6 (21.7)	9.6 (19.7)	50.0 (0.0)	57.4 (29.4)	35.7 (30.4)	5.0 (10.4)	41.3 (21.4)	29.8 (26.0)	5.7 (11.5)	55.5 (27.7)	43.7 (28.4)
	Median (range)	0.0 (0.0, 100.0)	14.5 (0.0, 75.0)	0.0 (0.0, 83.3)	5.0 (10.4, 0.0)	70.0 (0.0, 100.0)	30.0 (0.0, 100.0)	0.0 (0.0, 50.0)	45.4 (0.0, 80.1)	30.0 (0.0, 90.0)	0.0 (0.0, 50.0)	60.0 (0.0, 100.0)	50.0 (0.0, 100.0)

Abbreviations: AUS, Australia; CKD, chronic kidney disease; DD, dialysis dependent; DEU, Germany; EGY, Egypt; GBR, United Kingdom; GP, general population; ITA, Italy; NDD, non-dialysis dependent; SD, standard deviation; TWN, Taiwan; USA, United States of America; WAPI, Work Productivity and Activity Impairment

Table S8. CFPB Financial Well-Being Scale, linear regression analysis for patients vs general population cohorts

Variable	AUS	DEU	EGY	GBR	ITA	TWN	USA
Patients (vs Gen pop)							
Estimate	-6.337	-4.002	-0.705	-6.901	-5.988	-0.955	-10.100
Standard error	1.453	1.305	0.938	1.224	1.454	0.831	1.420
t value	-4.360	-3.068	-0.752	-5.637	-4.119	-1.149	-7.114
p value	< 0.001	0.002	0.452	< 0.001	< 0.001	0.251	< 0.001
Age							
Estimate	0.276	0.101	-0.142	0.351	0.225	0.289	0.635
Standard error	0.050	0.053	0.044	0.047	0.061	0.049	0.053
t value	5.581	1.894	-3.222	7.450	3.682	5.868	6.890
p value	< 0.001	0.059	0.001	< 0.001	< 0.001	< 0.001	< 0.001
Non-male							
Estimate	-2.083	-1.883	3.542	-6.638	-0.187	-2.148	-4.817
Standard error	1.488	1.365	0.933	1.447	1.480	0.999	1.449
t value	-1.400	-1.380	3.795	-4.857	-0.127	-2.150	-3.324
p value	0.163	0.169	< 0.001	< 0.001	0.899	0.032	< 0.001
Regional/rural							
Estimate	-4.355	-0.794	-7.109	1.814	3.704	-1.675	0.420
Standard error	1.651	1.288	4.566	1.377	1.593	1.067	1.458
t value	-2.638	-0.617	-1.557	1.317	2.325	-1.570	0.288
p value	0.009	0.538	0.120	0.189	0.021	0.117	0.774
Employed							
Estimate	1.340	4.449	3.669	0.028	8.015	3.479	2.879
Standard error	1.665	1.444	1.066	1.454	1.780	1.169	1.635
t value	0.805	3.080	3.442	0.019	4.503	2.976	1.761
p value	0.422	0.002	< 0.001	0.985	< 0.001	0.003	0.079

Abbreviations: AUS, Australia; CFPB, Consumer Financial Protection Bureau; DEU, Germany; EGY, Egypt; GBR, United Kingdom; ITA, Italy; TWN, Taiwan; USA, United States of America

Note: Estimates with a negative value indicate the group variable assessed is associated with a lower CFPB score and therefore associated with worse financial well-being. A larger t-value indicates a greater likelihood that the null hypothesis does not apply, and that a significant relationship may exist between the group variable and the CFPB score. Associations are considered statistically significant at a threshold of $p < 0.05$.

Table S9. FACIT-COST, linear regression analysis for dialysis dependent patient subgroups

Variable	AUS	DEU	EGY	GBR	ITA	TWN	USA
NDD (vs DD)							
Estimate	0.835	-3.351	-2.470	3.890	-0.310	3.368	-1.814
Standard error	1.887	1.426	1.290	1.458	1.677	1.063	1.883
t value	0.442	-2.350	-2.206	2.668	-0.185	3.168	-0.630
p value	0.659	0.020	0.028	0.008	0.854	0.002	0.337
Age							
Estimate	0.219	0.009	-0.174	0.236	0.061	0.158	0.277
Standard error	0.059	0.055	0.060	0.051	0.064	0.046	0.065
t value	3.678	0.171	-2.875	4.581	0.951	3.466	4.278
p value	< 0.001	0.865	0.004	< 0.001	0.343	< 0.001	< 0.001
Non-male							
Estimate	-1.273	-0.181	2.999	-4.581	-0.939	-1.249	-4.824
Standard error	1.647	1.526	1.588	1.440	1.525	0.862	1.600
t value	-0.773	-0.118	1.888	-3.182	-0.616	-1.448	-3.015
p value	0.441	0.906	0.060	0.002	0.539	0.149	0.002
Regional/rural							
Estimate	-2.250	-1.145	3.539	0.215	2.423	-3.563	-1.715
Standard error	1.726	1.344	6.561	1.424	1.701	0.904	1.549
t value	-1.304	-0.852	0.539	0.151	1.425	-3.940	-1.107
p value	1.940	0.395	0.590	0.880	0.157	< 0.001	0.270
Employed							
Estimate	3.288	1.197	3.980	-0.680	7.416	2.362	2.898
Standard error	1.756	1.383	1.593	1.454	1.943	0.982	1.877
t value	1.872	0.866	2.498	-0.468	3.816	2.406	1.544
p value	0.063	0.388	0.013	0.641	< 0.001	0.017	0.124

Abbreviations: AUS, Australia; DD, dialysis dependent; DEU, Germany; EGY, Egypt; FACIT-COST, Comprehensive Score for financial Toxicity-Functional Assessment of Chronic Illness Therapy; GBR, United Kingdom; ITA, Italy; NDD, non-dialysis dependent; TWN, Taiwan; USA, United States of America

Note: Estimates with a negative value indicate the group variable assessed is associated with a lower FACIT-COST score and therefore associated with greater financial distress. A larger t-value indicates a greater likelihood that the null hypothesis does not apply, and that a significant relationship may exist between the group variable and the FACIT-COST score. Associations are considered statistically significant at a threshold of $p < 0.05$.

Table S10. WPAI, caregivers (stratified by dialysis status) vs general population cohorts

Country		Absenteeism			Presenteeism			Work activity impairment			Activity impairment		
		GP	DD	NDD	GP	DD	NDD	GP	DD	NDD	GP	DD	NDD
AUS	Mean	3.0	16.9	6.3	12.9	45.2	20.0	12.0	34.6	18.4	13.1	40.0	47.4
	(SD)	(10.4)	(21.3)	(10.1)	(17.2)	(31.6)	(20.7)	(15.3)	(24.6)	(19.8)	(15.5)	(29.6)	(28.6)
	Median (range)	0.0 (0.0, 50.0)	11.8 (0.0, 95.2)	0.0 (0.0, 24.4)	10.0 (0.0, 60.0)	40.0 (0.0, 100.0)	15.0 (0.0, 60.0)	10.0 (0.0, 50.0)	30.0 (0.0, 80.1)	14.4 (0.0, 60.0)	10.0 (0.0, 50.0)	30.0 (0.0, 100.0)	50.0 (0.0, 90.0)
DEU	Mean	2.4	16.2	12.0	8.5	30.3	26.6	7.8	23.1	21.7	12.0	31.7	39.7
	(SD)	(9.6)	(17.4)	(13.5)	(14.5)	(25.6)	(18.8)	(13.0)	(18.4)	(13.1)	(18.3)	(27.0)	(26.7)
	Median (range)	0.0 (0.0, 50.0)	11.8 (0.0, 65.2)	10.0 (0.0, 60.0)	0.0 (0.0, 60.0)	30.0 (0.0, 90.0)	20.0 (0.0, 70.0)	0.0 (0.0, 50.0)	20.0 (0.0, 60.0)	18.4 (0.0, 54.1)	0.0 (0.0, 90.0)	20.0 (0.0, 100.0)	30.0 (0.0, 100.0)
EGY	Mean	20.8	13.9	11.8	19.4	39.0	39.1	14.0	31.4	31.2	21.0	49.4	32.4
	(SD)	(28.5)	(14.1)	(16.8)	(25.1)	(28.6)	(34.2)	(16.1)	(21.0)	(27.3)	(26.5)	(30.3)	(30.9)
	Median (range)	6.5 (0.0, 100.0)	13.8 (0.0, 50.0)	6.2 (0.0, 50.0)	10.0 (0.0, 100.0)	30.0 (0.0, 90.0)	20.0 (0.0, 80.0)	10.0 (0.0, 80.0)	28.8 (0.0, 76.2)	20.0 (0.0, 74.9)	10.0 (0.0, 100.0)	60.0 (0.0, 90.0)	20.0 (0.0, 90.0)
GBR	Mean	7.3	18.0	5.9	16.7	47.0	26.1	14.2	35.1	23.0	14.9	54.6	40.0
	(SD)	(17.2)	(22.3)	(9.7)	(24.7)	(27.6)	(23.1)	(22.2)	(20.4)	(19.3)	(22.6)	(24.1)	(21.2)
	Median (range)	0.0 (0.0, 66.7)	9.5 (0.0, 90.0)	0.0 (0.0, 29.4)	0.0 (0.0, 100.0)	40.0 (0.0, 100.0)	20.0 (0.0, 70.0)	0.0 (0.0, 100.0)	37.9 (0.0, 89.3)	20.0 (0.0, 62.9)	0.0 (0.0, 100.0)	60.0 (0.0, 100.0)	40.0 (0.0, 80.0)
ITA	Mean	3.6	18.7	9.2	11.2	54.3	35.5	9.9	41.4	31.6	11.2	56.0	38.2
	(SD)	(11.6)	(19.3)	(13.4)	(18.2)	(28.7)	(23.8)	(14.8)	(21.9)	(21.2)	(18.7)	(26.3)	(25.7)
	Median (range)	0.0 (0.0, 50.0)	12.0 (0.0, 51.4)	7.5 (0.0, 84.0)	0.0 (0.0, 80.0)	60.0 (0.0, 90.0)	30.0 (0.0, 90.0)	0.0 (0.0, 65.4)	45.1 (0.0, 75.2)	28.4 (0.0, 80.0)	0.0 (0.0, 80.0)	60.0 (0.0, 90.0)	30.0 (0.0, 100.0)
TWN	Mean	1.4	4.8	1.9	19.8	35.9	27.1	19.1	33.6	26.3	19.1	40.7	33.7
	(SD)	(4.3)	(8.8)	(4.3)	(24.7)	(14.6)	(19.2)	(23.5)	(12.1)	(18.3)	(25.0)	(13.9)	(17.8)
	Median (range)	0.0 (0.0, 20.0)	0.0 (0.0, 38.5)	0.0 (0.0, 16.7)	10.0 (0.0, 100.0)	40.0 (0.0, 70.0)	30.0 (0.0, 60.0)	10.0 (0.0, 100.0)	34.8 (0.0, 57.2)	30.0 (0.0, 60.0)	10.0 (0.0, 100.0)	40.0 (0.0, 70.0)	40.0 (0.0, 60.0)
USA	Mean	5.2	14.8	10.6	17.5	40.1	35.0	14.8	30.6	27.9	17.3	44.3	34.3
	(SD)	(13.6)	(22.8)	(18.7)	(27.5)	(32.0)	(28.0)	(22.7)	(23.8)	(17.5)	(27.7)	(28.4)	(24.2)
	Median (range)	0.0 (0.0, 57.1)	2.8 (0.0, 94.3)	0.0 (0.0, 50.0)	0.0 (0.0, 100.0)	30.0 (0.0, 100.0)	20.0 (10.0, 100.0)	0.5 (0.0, 90.0)	25.5 (0.0, 100.0)	20.0 (10.0, 62.5)	0.0 (0.0, 100.0)	50.0 (0.0, 100.0)	30.0 (0.0, 100.0)

Abbreviations: AUS, Australia; DD, dialysis dependent; DEU, Germany; EGY, Egypt; GBR, United Kingdom; GP, general population; ITA, Italy; NDD, non-dialysis dependent; SD, standard deviation; TWN, Taiwan; USA, United States of America; WPAI, Work Productivity and Activity Impairment

Table S11. CFPB Financial Well-Being Scale, linear regression analysis for caregivers vs general population cohorts

Variable	AUS	DEU	EGY	GBR	ITA	TWN	USA
Caregivers (vs Gen pop)							
Estimate	-1.372	3.311	-1.756	-4.517	4.227	-0.739	-0.566
Standard error	2.107	1.940	1.314	1.603	1.450	1.013	1.711
t value	-0.651	1.707	-1.336	-2.817	2.915	-0.729	-0.331
p value	0.516	0.089	0.183	0.005	0.004	0.467	0.740
Age							
Estimate	0.312	0.166	0.005	0.254	0.156	0.169	0.295
Standard error	0.079	0.081	0.065	0.063	0.058	0.051	0.063
t value	3.950	2.051	0.076	4.022	2.695	3.345	4.657
p value	< 0.001	0.042	0.940	< 0.001	0.008	0.001	< 0.001
Non-male							
Estimate	-3.620	0.409	-0.378	-1.986	-1.431	-0.148	-2.228
Standard error	2.198	1.968	1.355	1.605	1.834	1.024	1.749
t value	-1.647	0.208	-0.279	-1.238	-0.781	-0.145	-1.274
p value	0.103	0.835	0.780	0.217	0.436	0.885	0.204
Regional/rural							
Estimate	-0.724	3.012	1.481	-2.471	0.090	-4.245	0.061
Standard error	2.315	1.996	2.765	1.618	1.455	1.099	1.848
t value	-0.313	1.509	0.536	-1.527	0.062	-3.864	0.033
p value	0.755	0.133	0.593	0.128	0.951	< 0.001	0.974
Employed							
Estimate	-4.194	-1.168	1.714	-0.050	1.376	-1.045	0.110
Standard error	2.875	2.299	1.533	1.984	1.601	15.990	2.293
t value	-1.459	-0.508	1.118	-0.025	0.860	-0.654	0.048
p value	0.148	0.612	0.265	0.980	0.391	0.514	0.962

Abbreviations: AUS, Australia; CFPB, Consumer Financial Protection Bureau; DEU, Germany; EGY, Egypt; GBR, United Kingdom; ITA, Italy; TWN, Taiwan; USA, United States of America

Note: Estimates with a negative value indicate the group variable assessed is associated with a lower CFPB score and therefore associated with worse financial well-being. A larger t-value indicates a greater likelihood that the null hypothesis does not apply, and that a significant relationship may exist between the group variable and the CFPB score. Associations are considered statistically significant at a threshold of $p < 0.05$.